Akinobu Hamada

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy

Joan Miguel Romero, Jamie Magrill, Nikita Kalashnikov, Michael Luo et autres

Patient-derived xenografts (PDX) and patient-derived organoids (PDO) are widely used to model cancer and predict treatment response in matched patients. However, their predictive accuracy has not been systematically studied nor compared. We conducted a systematic review and meta-analysis of studies using PDX …

ca, us, de, no, it, es, jp, fr, se, fi, sg, au (code pays fourni par la source)

Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and κ-opioid counter-regulation

Hitoshi Makabe, Michiko Narita, Yasuyuki Nagumo, Masanori Fujiwara et autres

Severe pain in patients with breast cancer is associated with poorer survival outcomes, yet the mechanisms linking nociceptive signaling to tumor progression remain unclear. In a clinical cohort, breast cancer patients whose moderate or severe pain improved under specialized palliative care exhibited …

jp, gb, us (code pays fourni par la source)

Real-world pharmacokinetics of ramucirumab in combination with erlotinib and docetaxel for advanced non-small cell lung cancer: a prospective cohort study

Kazumasa Akagi, Shinnosuke Takemoto, Mayu Ohuchi, Shigehiro Yagishita et autres

jp, gb (code pays fourni par la source)

Chromosome 15q15 Deletion Drives Brain Metastasis in NSCLC

Jun Miyakoshi, Kouya Shiraishi, Akifumi Mochizuki, Akiko Tateishi et autres

Introduction Brain metastasis (BM) is a devastating complication of non-small cell lung cancer (NSCLC), particularly in NSCLC tumors harboring EGFR mutations. However, the genomic alterations driving BM remain poorly understood. Methods We analyzed three independent cohorts of resected NSCLCs from Asian patients, …

jp, gb, us (code pays fourni par la source)

Abstract 4607: Pharmacokinetic analysis of palbociclib and association with safety/efficacy in patients with HR-positive/HER2-negative advanced breast cancer: Result from PATHWAY trial

Kazuki Sudo, Shigehiro Yagishita, Emi Noguchi, Naohito Yamamoto et autres

Abstract Background: We recently reported that the combination of palbociclib and tamoxifen significantly extended progression-free survival (PFS) in patients with HR+/HER2- advanced breast cancer, in both pre-, peri-, and post- menopausal Asian patients versus tamoxifen alone (PATHWAY trial, NCCH1607, NCT03423199). Here, we …

jp, tw, kr, sg (code pays fourni par la source)

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Takayasu Nishimaki, Hitoshi Sasano, Sonoko Harada, Tomohito Takeshige et autres

Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab, which targets IL-5 and can manage uncontrolled …

jp (code pays fourni par la source)

Abstract PO1-14-01: Clonal Architecture of circulating tumor DNA predicts Early Progression on Tamoxifen With or Without Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer: NCCH1607/PATHWAY trial

Yoon Sim Yap, Yuki Kojima, Akinobu Hamada, Hirofumi Mukai et autres

Abstract Objective: Some patients with poor prognosis hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) experience early disease progression on the combination of CDK4/6 inhibitors and endocrine therapy. We aimed to determine whether clonal architecture assessed by …

sg, us, gb, jp, tw (code pays fourni par la source)

Severe induction of aberrant DNA methylation by nodular gastritis in adults

Akiko Sasaki, Hideyuki Takeshima, Satoshi Yamashita, Chikamasa Ichita et autres

jp, de (code pays fourni par la source)

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study

Yuki Katsuya, Tatsuya Yoshida, Atsuo Takashima, Kan Yonemori et autres

BACKGROUND: Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines. METHODS: This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory …

us, jp (code pays fourni par la source)

Need for Ethical Governance on the Implementation and Use of Patient-derived Xenograft (PDX) Models for Anti-cancer Drug Discovery and Development: Ethical Considerations and Policy Proposal

Kenji Matsui, Shigehiro Yagishita, Akinobu Hamada

as the trust property of patients of origin and shall not be subjected directly to monetary transactions. Third, PDX models must be treated with due care in an ethical manner in line with experimental animal ethics. Finally, the implementation and use of …

gb (code pays fourni par la source)

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study

Yuki Katsuya, Tatsuya Yoshida, Atsui Takashima, Kan Yonemori et autres

jp (code pays fourni par la source)

Precancerous nature of intestinal metaplasia with increased chance of conversion and accelerated DNA methylation

Chihiro Takeuchi, Satoshi Yamashita, Hideyuki Takeshima, Akiko Sasaki et autres

Objective The presence of intestinal metaplasia (IM) is a risk factor for gastric cancer. However, it is still controversial whether IM itself is precancerous or paracancerous. Here, we aimed to explore the precancerous nature of IM by analysing epigenetic alterations. Design Genome-wide …

jp (code pays fourni par la source)